StockNews.AISignal intelligence
Oruka Therapeutics Inc. · NASDAQ
Browse public ORKA signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Oruka Therapeutics reported positive Week 16 results from EVERLAST-B for ORKA-001 in moderate-to-severe plaque psoriasis, with the 600 mg high-dose achieving 61% PASI-100 and strong PASI-90 outcomes. The company plans Phase 3 trials in early 2027 and expects 52-week data from EVERLAST-A in December 2026, setting up near-term catalysts and mid-term upside tied to regulatory progress.
View signal analysisOruka Therapeutics reported week 28 data from the Phase 2a ORKA-001 psoriasis trial, showing sustained activity with 71.4% achieving PASI 100 and 87.3% attaining PASI 90. The safety profile remains favorable, with no injection-site reactions and only two serious adverse events deemed unrelated. Key upcoming readouts—EVERLAST-A at 52 weeks (Dec 2026) and EVERLAST-B data in Q4 2026—could meaningfully influence ORKA's valuation if durability holds.
View signal analysisOruka Therapeutics reported strong efficacy for its ORKA-001 treatment, achieving 63.5% complete skin clearance among participants, with favorable safety data. The stock surged 39% as analysts raised price targets, highlighting a competitive edge in psoriasis treatments with a potential for annual dosing.
View signal analysis